Prosecution Insights
Last updated: April 19, 2026

Iovance Biotherapeutics, Inc.

11 pending office actions

Portfolio Summary

11
Total Pending OAs
5
Final Rejections
6
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18590860 SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY HUYNH, EMILY 3683 Final Rejection Feb 28, 2024
18262843 ADJUVANT THERAPY FOR CANCER WEN, SHARON X 1641 Non-Final OA Jul 25, 2023
18256853 TREATMENT OF CANCERS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES CUNNINGCHEN, KATHLEEN MARY 1646 Non-Final OA Jun 09, 2023
18247878 TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES AEDER, SEAN E 1642 Non-Final OA Apr 04, 2023
17997731 PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY ZHU, JIANJIAN 1631 Non-Final OA Nov 01, 2022
17997648 SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS RAHMAN, MASUDUR 1633 Final Rejection Oct 31, 2022
17829087 RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES KELLY, ROBERT M 1638 Final Rejection May 31, 2022
17771723 GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY BERTOGLIO, VALARIE E 1632 Final Rejection Apr 25, 2022
17267699 Expansion of TILs from Cryopreserved Tumor Samples O'NEILL, MARISOL ANN 1633 Final Rejection Jan 10, 2022
17440639 SEQUENTIAL HETEROLOGOUS BOOST ONCOLYTIC VIRAL IMMUNOTHERAPY GILL, RACHEL B 1671 Non-Final OA Sep 17, 2021
17415175 Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof KOLKER, DANIEL E 1645 Non-Final OA Jun 17, 2021

Managing Iovance Biotherapeutics, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month